ReviewInternational journal of nanomedicine2026
Combating Bacterial Infection with Metabolism-Regulating Nanomaterials.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of antibiotic resistance presents a major global health challenge. Bacterial survival is closely tied to their metabolic reprogramming under stress, which enhances their environmental adaptability. While current antibacterial strategies are often limited by bacterial resistance, nanomaterials offer a promising alternative due to their unique physicochemical properties. These functionalized nanoagents can precisely deliver antimicrobials and selectively interfere with metabolic processes of bacteria, including aerobic and anaerobic metabolism, peptidoglycan synthesis, metal ion homeostasis, and nitrogen metabolism. By interfering with energy metabolism, nutrient uptake, and quorum sensing, they can effectively eliminate drug-resistant and persister bacteria. In this review, we summarize the recent advances in metabolic-regulating antibacterial treatment. Then, the clinical translation challenges facing nanotechnology-driven metabolic regulation strategies are discussed. Finally, we hope this review offers forward-looking perspectives on the development of non-antibiotic antibacterial nanoagents for future bacterial metabolic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.